Changed expression of TRF1, TRF2, and TIN2 found in human cancers, such as increased expression of TRF1 in chronic lymphocytic leukemia cells [10] and decreased expression in renal cell carcinoma [11], raised the possibility of using these components as potential therapeutic targets for cancer treatment [12]. This evidence concerns the gene TERF2 and cancer.